DOCSLIB.ORG

What Is an Anti-Aging Treatment?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
What Is an Anti-Aging Treatment? Experimental Gerontology 58 (2014) 14–18 Contents lists available at ScienceDirect Experimental Gerontology journal homepage: www.elsevier.com/locate/expgero What is an anti-aging treatment? David Gems Institute of Healthy Ageing, and Genetics, Evolution and Environment, University College London, Gower Street, London WC1E 6BT, United Kingdom article info abstract Article history: Key objectives of biogerontology are to understand the biology of aging and to translate scientific insight into in- Received 15 November 2013 terventions that improve late-life health — or anti-aging treatments. In this context, when considering the prob- Received in revised form 25 June 2014 lem of how to effect translational research, it is useful to have a clear, consensus view on what exactly constitutes Accepted 10 July 2014 an anti-aging treatment. This essay critically assesses the understanding of this concept common among Available online 11 July 2014 biogerontologists, and proposes a new definition. A current conception of anti-aging treatment imagines a prima- Section Editor: T.E. Johnson ry cause of aging that is causally upstream of, and the cause of, all age-related pathology. Intervening in this aging process thus protects against the totality of age-related diseases. However, this underlying aging process remains Keywords: an abstraction. By contrast, what is demonstrable is that interventions in model organisms can improve late-life Aging health and extend lifespan. Furthermore, a safe deduction is that treatments that extend lifespan do so by reduc- Biogerontology ing age-related pathology, both florid and subtle. What is currently identifiable about aging (i.e. senescence) is Disease that it is a very complex disease syndrome, likely involving a number of biological mechanisms. Treatments Prevention that substantially extend lifespan must suppress multiple pathologies that otherwise limit lifespan, but whether Translation they suppress the entire aging process remains undemonstrated. A more pragmatic and realistic definition of anti-aging treatment is any preventative approach to reduce late-life pathology, based on the understanding that senescence is a disease syndrome. This definition would encompass preventative approaches aimed at both broad and narrow spectra of age-related pathologies. Its adoption would facilitate translation, since it would shift the emphasis to medical practice, particularly the introduction of preventative approaches. Narrow spectrum anti-aging treatments (e.g. the cardiovascular polypill) could establish a practice that eventually ex- tends to broader spectrum anti-aging treatments (e.g. dietary restriction mimetics). © 2014 Elsevier Inc. All rights reserved. 1. Introduction Arguably, fulfillment of these two objectives, while necessary for translation, is far from being sufficient. This is because relative to con- Pathologies of aging underlie much of the disease burden world- ventional views about the nature of aging, the approach of anti-aging wide. Work on animal models has revealed interventions that lead to therapies is a radical one. Such conventions affect both public and polit- an increase in healthy lifespan (Kenyon, 2010). Such studies suggest ical attitudes towards aging and medical practice. Adoption by the med- that by slowing the underlying process of aging one can achieve broad ical establishment of an anti-aging approach to improve late-life health spectrum protection against diseases of aging (Butler et al., 2008). would involve radical, even revolutionary change. It would, for example, Understandably, there is a strong desire among biogerontologists to involve a re-conceptualization of the nature of aging and the relation- shift from pure to translational research, and to identify paths that ship between aging and disease, the introduction of a preventative ap- would lead to clinical trials of anti-aging therapies. This aspiration proach to age-related disease, a more active role of the patient in underpinned the recent conference Interventions to Slow Aging in managing their own late-life health — and even teaching medical stu- Humans: Are we Ready? held in October 8–13th 2013 in Erice, Sicily dents about the biology of aging (currently medical students are taught (organized by Valter Longo, Luigi Fontana and Donald Ingram). little about the biological basis of the most prevalent cause of disease). In order to promote translational research the meeting was oriented One impediment to translation, noted by one speaker at the confer- to two main objectives. First, to survey the (now) many different ap- ence, Brian Kennedy, Director of the Buck Institute for Research on proaches in the laboratory that have been to extend lifespan in animal Aging, is the lack of clarity and consensus about the definition of anti- models, and seek a consensus about which approaches would be most aging treatment. One might mistake this for a minor issue of semantics, promising to test first in humans. Second, to develop a consensus on but here I will argue the opposite: that a good definition of anti-aging the most appropriate biomarkers of aging to use as a readout of treat- treatment is important not only to clearly define the goals of ment efficacy. biogerontology, but also to enable them to be fulfilled. In this essay, I will first give a brief account of the standard biogerontological concep- E-mail address: [email protected]. tion of anti-aging medicine (at least, as I have understood it), and then http://dx.doi.org/10.1016/j.exger.2014.07.003 0531-5565/© 2014 Elsevier Inc. All rights reserved. D. Gems / Experimental Gerontology 58 (2014) 14–18 15 make a critical assessment of this definition. I will then propose an alter- people die without pathology is absurd: in biological terms, by defini- native definition, one that is, arguably, more realistic and pragmatic. tion, endogenous factors harmful enough to cause death must entail se- vere pathology. Put simply: “No one dies from healthy senescence” 2. Anti-aging treatments: a standard view from biogerontology (Blagosklonny, 2006). The notion of death from “pure aging” (i.e. aging without pathology) is surely a myth. One source of this myth A common conception among biogerontologists of anti-aging treat- may well be that some aspects of aging are more identifiable as pathol- ment is based on a straightforward premise: that a biological process, ogies than others. As examples, one cannot fail to identify cancer and aging, gives rise in later life to a broad spectrum of diseases. This being macular degeneration as pathologies, but this is less the case for so, any intervention that inhibits aging itself will reduce incidence of a sarcopenia and osteoporosis. broad spectrum of late-life diseases (Butler et al., 2008). Consistent Human health has been defined in terms not only of the absence of with this premise, a variety of interventions improve late-life health disease, but also of the presence of a level of function that is typical of and extend lifespan in a range of animal models. For example, dietary human beings of a given age and gender (Boorse, 1977). By this view, restriction (caloric restriction) has long been known to slow aging and given that all old people experience it, aging is a normal process and improve late-life health in rodents, and may be effective in rhesus mon- therefore distinct from disease — despite the fact that it is accompanied keys (Bodkin et al., 2003; Colman et al., 2009; Mattison et al., 2012)and by a broad spectrum of diseases. Clues to a resolution of this paradox possibly humans (Berrington de Gonzalez et al., 2010; Fontana et al., may be found in the evolutionary theory of aging, which provides a bi- 2004). There seems no reason in principle why some form of anti- ological perspective upon the purpose and meaning of the aging process aging treatment should not be efficacious in humans, and lead to great (Caplan, 2005). According to the evolutionary theory, aging is a conse- improvements in late-life health in times to come. Even so, closer scru- quence of a reduction in the force of selection against mutations with tiny of the concept of anti-aging treatment reveals some weaknesses in deleterious effects later in life (Medawar, 1952; Partridge and Barton, this standard view, involving the following questions. 1993). This leads to accumulation within populations of alleles with del- eterious effects later in life — particularly alleles that also have beneficial i) Is there a real distinction between age-related disease and aging? effects on reproductive fitness early in life (Williams, 1957). The evolu- ii) Where should one draw the line between anti-aging treatment tionary theory provides the bleak insight that aging serves no purpose and conventional treatments for late-life diseases? in terms of fitness, but instead is a lethal genetic disease that afflicts iii) To what extent do treatments that extend lifespan in animal all human beings. Arguably, the significance of the universality of models slow aging? human aging is not that aging is not a disease, but rather that it is a spe- iv) Which is a better defining characteristic of anti-aging treat- cial form of disease. To argue that aging is not a disease by virtue of its ments: that they inhibit the central process of aging, or that universality is as unhelpful as it is to argue that the Basenji is not a they prevent age-related diseases? dog because it does not bark. In the next section, I will start by attempting to clarify the relation- In short, senescence is an inherently pathological process. Thus, ship between aging and age-related pathology. “healthy aging” in the sense of “healthy senescence” is an oxymoron. However, in terms of calendar aging or age-related change, healthy 3. The myth of “pure aging” aging is a desirable goal. One reading of the history of ideas on aging is that apologism has generated not only the standard (and nonsensical) Conceptually, the idea of protecting against age-related diseases by medical view of aging as distinct from pathology (“healthy senes- retarding aging remains somewhat fuzzy due to the lack of a clear un- cence”), but also the conception by biogerontologists of pathology- derstanding of what aging actually is.
Load more

Recommended publications
  • Symposium on Aging June 19, 2015 Symposium on Aging the Paul F
    The 2015 Harvard / Paul F. Glenn Symposium on Aging June 19, 2015 Symposium on Aging The Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Agenda 10th Anniversary Symposium Welcome to the 10th Annual Harvard/Paul F. Glenn Symposium on Aging. June 19, 2015 Each year, the Paul F. Glenn Laboratories host the Harvard Symposium 9:00 - 5:00 on Aging with a mission to present new advances in aging research and to stimulate collaborative research in this area. The symposium has grown over the past 10 years to be one of the biggest events at Harvard Medical School. We have been fortunate to have many of the leaders in the aging field speak 9:00 – 9:45 a.m. Introduction at the symposia and today is no exception. We wish to acknowledge the generosity and vision of Paul F. Glenn, Mark 9:45 – 10:15 a.m. Ensuring the Health of the Germ-line Collins and Leonard Judson for their unwavering support of aging research Cynthia Kenyon, Ph.D. through the Paul F. Glenn Foundation. Thanks to their support, we now have a vibrant community of researchers who study aging and age-related 10:15 – 10:45 a.m. C. elegans Surveillance of Core Cellular diseases. Since the inception of the Paul F. Glenn labs at Harvard in 2005, Components to Detect and Defend Pathogen this network has grown to include aging studies at the Albert Einstein Attacks, and How This Relates to Longevity College of Medicine, the Buck Institute, the Mayo Clinic, Massachusetts Gary Ruvkun, Ph.D.
    [Show full text]
  • David Sinclair Can Dramatically Extend the Life Span of Yeast
    News Focus Lenny Guarente and his former postdoc David Sinclair can dramatically extend the life span of yeast. They’re battling over how this works, and competing head-to-head to grant extra years to humans Aging Research’s Family Feud BOSTON AND CAMBRIDGE,MASSACHUSETTS—At tenure-track spot on Harvard’s faculty in late share many traits common among successful 34, David Sinclair is a rising star. His spa- 1999. He then made clear that his old profes- scientists. Both are deeply ambitious, relent- cious ninth-floor office at Harvard Medical sor’s pet theories weren’t off limits. At a lessly competitive, and supremely self-confi- School boasts a panoramic Boston view. His meeting at Cold Spring Harbor Laboratory dent. Both savor the limelight. Both love sci- rapidly growing lab pulled off the feat of pub- in late 2002, Sinclair surprised Guarente by ence and show little interest in other pursuits. lishing in both Nature and Science last year, challenging him on how a key gene Guarente Still, they’ve retained something of the and it made headlines around the world with discovered extends life in yeast. That sparked parent-child relationship that can shape in- a study of the possible antiaging properties of a bitter dispute that crescendoed this winter, teractions between senior researchers and a molecule found in red wine. In a typical when the pair published dueling papers. their students. Like a father dismayed when day, he fields calls from a couple practicing a Researchers who study aging are finding his son joins a punk rock band, and then dis- radical diet to extend life span, and from an the quarrel both intellectually provocative and mayed further when it attracts devoted fans actor hunting for antiaging pills and the a lively source of gossip.
    [Show full text]
  • Genes That Act Downstream of DAF-16 to Influence the Lifespan Of
    articles Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans Coleen T. Murphy*, Steven A. McCarroll†, Cornelia I. Bargmann†, Andrew Fraser‡, Ravi S. Kamath‡, Julie Ahringer‡, Hao Li* & Cynthia Kenyon* * Department of Biochemistry and Biophysics, and † Department of Anatomy and Howard Hughes Medical Institute, University of California, San Francisco, California 94143-2200, USA ‡ Wellcome CRC Institute and Department of Genetics, University of Cambridge, Tennis Court Road, Cambridge CB2 1QR, UK ........................................................................................................................................................................................................................... Ageing is a fundamental, unsolved mystery in biology. DAF-16, a FOXO-family transcription factor, influences the rate of ageing of Caenorhabditis elegans in response to insulin/insulin-like growth factor 1 (IGF-I) signalling. Using DNA microarray analysis, we have found that DAF-16 affects expression of a set of genes during early adulthood, the time at which this pathway is known to control ageing. Here we find that many of these genes influence the ageing process. The insulin/IGF-I pathway functions cell non- autonomously to regulate lifespan, and our findings suggest that it signals other cells, at least in part, by feedback regulation of an insulin/IGF-I homologue. Furthermore, our findings suggest that the insulin/IGF-I pathway ultimately exerts its effect on lifespan by upregulating a wide variety of genes, including cellular stress-response, antimicrobial and metabolic genes, and by downregulating specific life-shortening genes. The recent discovery that the ageing process is regulated hormonally never been tested directly; for example, by asking whether stress by an evolutionarily conserved insulin/IGF-I signalling pathway1–3 response genes are required for the longevity of daf-2 mutants.
    [Show full text]
  • From Here to Immortality: Anti-Aging Medicine
    FromFrom HereHere toto Immortality:Immortaalitty: AAnti-AgingAnnntti-AAgging MMedicineedicine Anti-aging medicine is a $5 billion industry. Despite its critics, researchers are discovering that inter ventions designed to turn back time may prove to be more science than fiction. By Trudie Mitschang 14 BioSupply Trends Quarterly • October 2013 he symptoms are disturbing. Weight gain, muscle Shifting Attitudes Fuel a Booming Industry aches, fatigue and joint stiffness. Some experience The notion that aging requires treatment is based on a belief Thear ing loss and diminished eyesight. In time, both that becoming old is both undesirable and unattractive. In the memory and libido will lapse, while sagging skin and inconti - last several decades, aging has become synonymous with nence may also become problematic. It is a malady that begins dete rioration, while youth is increasingly revered and in one’s late 40 s, and currently 100 percent of baby boomers admired. Anti-aging medicine is a relatively new but thriving suffer from it. No one is immune and left untreated ; it always field driven by a baby- boomer generation fighting to preserve leads to death. A frightening new disease, virus or plague? No , its “forever young” façade. According to the market research it’s simply a fact of life , and it’s called aging. firm Global Industry Analysts, the boomer-fueled consumer The mythical fountain of youth has long been the subject of base will push the U.S. market for anti-aging products from folklore, and although it is both natural and inevitable, human about $80 billion now to more than $114 billion by 2015.
    [Show full text]
  • Alchemy of Aging
    BOOK REVIEW Alchemy of aging The twists and turns of the discovery of telomerase, the cloning of the gene and the demonstration of its immortalizing Merchants of Immortality: Chasing power in cell culture systems are well told. Along the way, we the Dream of Human Life Extension learn of the squabbles, too. A sad axiom of modern biology, reflects Hall, is that the hotter the field, the ruder the behavior of Stephen S Hall its practitioners. Sad, perhaps, but as Hall very well knows, it Houghton Mifflin Company, 2003 makes for good copy. Although Hall documents his sources exhaustively, in more than 439 pp. hardcover, $25.00 50 pages of notes, his scientific range is limited. For example, he ISBN 0-61809-524-1 does not do as much as is needed to put the telomerase work into context. As the field has advanced, it has emerged that there is much Reviewed by Tom B L Kirkwood more to controlling cell proliferation than telomerase and that there is much more to tissue aging than just the Hayflick Limit. Unquestionably, the work included in Hall’s account is of great sig- nificance. But when and how it might lead to any real prospect of http://www.nature.com/naturemedicine For a work of engaging and painstaking science journalism, one intervention to extend human lifespan is anybody’s guess. Some of would have to search far to find anything that beats Stephen S. Hall’s the most interesting research in the field of aging is being done on Merchants of Immortality.This is the good news.
    [Show full text]
  • Real-Time Egg Laying Dynamics in Caenorhabditis Elegans
    UNIVERSITY OF CALIFORNIA, IRVINE Real-time egg laying dynamics in Caenorhabditis elegans DISSERTATION submitted in partial satisfaction of the requirements for the degree of DOCTOR OF PHILOSOPHY in Biomedical Engineering by Philip Vijay Thomas Dissertation Committee: Professor Elliot Hui, Chair Professor Olivier Cinquin Professor Abraham Lee 2015 c 2015 Philip Vijay Thomas TABLE OF CONTENTS Page LIST OF FIGURES iv ACKNOWLEDGMENTS v CURRICULUM VITAE vi ABSTRACT OF THE DISSERTATION viii 1 Introduction and motivation 1 1.1 The impact of C. elegans in aging and lifespan studies along with current limitations . 1 1.2 Starvation and its effect on worms . 4 1.3 Microfabricated systems for C. elegans biology . 5 2 Real-time C. elegans embryo cytometry to study reproductive aging 7 2.1 High capacity low-weight passive bubble trap . 8 2.2 Microfluidic device layout . 10 2.3 Tuning habitat exit sizes to flush out embryos while retaining worms . 11 2.4 Equal flow resistance to make identical habitats . 12 2.5 Video enumeration of eggs . 13 2.6 Switching between discrete and continuously varying media concentrations . 15 3 Optimizing worm health in C. elegans microfluidics 17 3.1 E. coli densities of 1010 cells/mL maintain egg-laying in liquid worm culture 18 3.2 E. coli biofilms in devices . 19 3.3 Amino acid addition to S-media, γ irradiation of bacteria, and elevated syringe temperatures are ineffective in reducing biofilms in devices . 20 3.4 Use of a curli major subunit deletion strain significantly reduces biofilm in S-media . 23 4 Conclusions and future directions 26 Bibliography 30 ii A Appendix Title 41 A.1 Methods .
    [Show full text]
  • 11/05/09 Agenda Attachment 6
    Bioinformatics @ UCSF: Faculty Multidisciplinary graduate study in biological composition, structure, David Agard function and evolution at the [email protected] molecular and systems levels Professor, Biochemistry & Biophysics Apply Now Structure, function, and folding of proteins, chromosomes, and About the Program centrosomes Training Program: Program Overview Core Curriculum Nadav Ahituv Electives [email protected] Seminars & Journal Club Assistant Professor, Bioengineering and Therapeutic Sciences Academic Progression & Procedures Deciphering the role of gene regulatory sequences in human People: biology and disease Students Faculty Alumni Patricia Babbitt Current Events [email protected] Admission Information Professor, Bioengineering and Therapeutic Sciences and Links Pharmaceutical Chemistry Contact Computational and experimental analysis of protein NEWS: UCSF wins HHMI Award for its superfamilies for functional inference and enzyme design Integrative Program in Complex Biological Systems Bruce Conklin [email protected] Associate Professor, Gladstone Institute of Cardiovascular Disease, Medicine & Pharmacology Combining the tools of molecular biology, genetics, bioinformatics, and physiology to answer fundamental issues in pharmacology. Joe DeRisi [email protected] Hughes Investigator, Associate Professor, Biochemistry & Biophysics Malaria gene expression profiling, functional genomics, microarrays Ken Dill [email protected] Professor, Pharmaceutical Chemistry Statistical mechanics of biomolecules, protein
    [Show full text]
  • Curriculum Vitae K. Adam Bohnert Education 2003-2007 BS, Summa
    Curriculum Vitae K. Adam Bohnert Education 2003-2007 BS, summa cum laude, Biology, Rhodes College, Memphis, TN 2007-2013 PhD, Cell & Developmental Biology, Vanderbilt University, Nashville, TN 2013-2017 Postdoctoral training, Dr. Cynthia Kenyon’s laboratory, University of California, San Francisco, and Calico Life Sciences, San Francisco Bay Area, CA Research Experience 2005-2006 NSF-REU Intern, Dr. Costantino Vetriani’s laboratory, Institute of Marine and Coastal Sciences, Rutgers, The State University of New Jersey Research topic: Microbial diversity at deep-sea hydrothermal vents 2005-2007 Undergraduate Student Research Assistant, Dr. Rosanna Cappellato’s laboratory, Department of Biology, Rhodes College Research topic: Ecosystem services of urban forests 2007-2013 Graduate Student, Dr. Kathleen Gould’s laboratory, Department of Cell and Developmental Biology, Vanderbilt University Research topic: Control of cell growth and division in fission yeast 2013-2017 Postdoctoral Scholar and Jane Coffin Childs Fellow, Dr. Cynthia Kenyon’s laboratory, University of California, San Francisco, and Calico Life Sciences Research topic: Germline rejuvenation in C. elegans Honors, Awards, and Research Support 2003-2007 National Merit Scholarship 2003-2007 Morse Scholarship (full-tuition scholarship), Rhodes College 2004 Award for Excellence in First-Year Biology, Rhodes College 2006 Michael E. Hendrick Award for Organic Chemistry, Rhodes College 2006-2007 Barry M. Goldwater Scholarship 2007 Outstanding Biology Senior Award, Rhodes College 2007 Phi
    [Show full text]
  • 2 the Biology of Ageing
    The biology of ageing 2 Aprimer JOAO˜ PEDRO DE MAGALHAES˜ OVERVIEW .......................................................... This chapter introduces key biological concepts of ageing. First, it defines ageing and presents the main features of human ageing, followed by a consideration of evolutionary models of ageing. Causes of variation in ageing (genetic and dietary) are reviewed, before examining biological theories of the causes of ageing. .......................................................... Introduction Thanks to technological progress in different areas, including biomed- ical breakthroughs in preventing and treating infectious diseases, longevity has been increasing dramatically for decades. The life expectancy at birth in the UK for boys and girls rose, respectively, from 45 and 49 years in 1901 to 75 and 80 in 1999 with similar fig- ures reported for other industrialized nations (see Chapter 1 for further discussion). A direct consequence is a steady increase in the propor- tion of people living to an age where their health and well-being are restricted by ageing. By the year 2050, it is estimated that the per- centage of people in the UK over the age of 65 will rise to over 25 per cent, compared to 14 per cent in 2004 (Smith, 2004). The greying of the population, discussed elsewhere (see Chapter 1), implies major medical and societal changes. Although ageing is no longer considered by health professionals as a direct cause of death (Hayflick, 1994), the major killers in industrialized nations are now age-related diseases like cancer, diseases of the heart and 22 Joao˜ Pedro de Magalhaes˜ neurodegenerative diseases. The study of the biological mechanisms of ageing is thus not merely a topic of scientific curiosity, but a crucial area of research throughout the twenty-first century.
    [Show full text]
  • The Genetics of Ageing Cynthia J
    INSIGHT REVIEW NATURE|Vol 464|25 March 2010|doi:10.1038/nature08980 The genetics of ageing Cynthia J. Kenyon1 The nematode Caenorhabditis elegans ages and dies in a few weeks, but humans can live for 100 years or more. Assuming that the ancestor we share with nematodes aged rapidly, this means that over evolutionary time mutations have increased lifespan more than 2,000-fold. Which genes can extend lifespan? Can we augment their activities and live even longer? After centuries of wistful poetry and wild imagination, we are now getting answers, often unexpected ones, to these fundamental questions. For many years, molecular biologists interested in regulatory mecha- that dietary restriction is imposed. In C. elegans, for example, one nutrient nisms did not study ageing, as the tissue decline associated with ageing sensor extends lifespan in response to life-long food limitation, another suggested a passive, entropic process of deterioration that occurred in in response to every-other-day feeding and a third if dietary restriction a haphazard way. We know now, however, that the ageing process, like begins in middle age11. so many other biological processes, is subject to regulation by classical Many other conditions can increase lifespan, including heat12–14 and signalling pathways and transcription factors. Many of these pathways oxidative stress15, low ambient temperature, chemosensory signals16, were first discovered in small, short-lived organisms such as yeast, thermosensory signals17, signals from the reproductive system18,19 and worms and flies, but a remarkable fraction turn out to extend lifespan reductions in the rates of respiration19–21 or translation3,22–24.
    [Show full text]
  • Could a Hormone Point the Way to Life Extension?
    INSIGHT elife.elifesciences.org LONGEVITY Could a hormone point the way to life extension? Mice that have been genetically modified to produce high levels of fibroblast growth factor-21 live longer than mice with normal levels of this hormone. CYNTHIA KENYON stress or a shortage of energy, can extend life- Related research article Zhang Y, Xie Y, span in worms, flies and mice. Perhaps pharma- Berglund ED, Coate KC, He TT, Katafuchi T, ceutical techniques could be used to extend Xiao G, Potthoff MJ, Wei W, Wan Y, Yu RT, human lifespans by modifying these or other Evans RM, Kliewer SA, Mangelsdorf DJ. life-extension pathways. 2012. The starvation hormone, fibroblast Now, writing in eLife, Yuan Zhang of the growth factor-21, extends lifespan in University of Texas Southwestern (UTSW) Medical mice. eLife 1:e00065. doi: 10.7554/eLife. Center and co-workers report that a hormone, 00065 called fibroblast growth factor-21 (FGF-21), can extend lifespan in mice (Zhang et al., 2012). When Image Lifespans of normal mice (blue line) food is withheld from an animal for 12 hours or and mice overexpressing FGF-21 (red) longer, liver cells produce this hormone, which then mobilizes fat stores in the liver, and promotes ill it be possible to slow the rate of the synthesis of glucose and ketones. FGF-21 also human aging and extend lifespan? reduces basal insulin levels and increases insulin WMaybe. Assuming that the first meta- sensitivity. In addition, it suppresses further growth zoans had short lifespans, gene changes have of the mice by preventing growth hormone from already extended our lifespans dramatically.
    [Show full text]
  • Revisiting the Hayflick Limit
    bioRxiv preprint doi: https://doi.org/10.1101/2021.05.03.442497; this version posted May 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Revisiting the Hayflick Limit: Insights from an Integrated Analysis of Changing Transcripts, Proteins, Metabolites and Chromatin. Michelle Chan, Han Yuan*, Ilya Soifer*, Tobias M. Maile, Rebecca Y. Wang, Andrea Ireland, Jonathon O’Brien, Jérôme Goudeau, Leanne Chan, Twaritha Vijay, Adam Freund, Cynthia Kenyon, Bryson Bennett, Fiona McAllister, David R. Kelley, Margaret Roy, Robert L. Cohen, Arthur D. Levinson, David Botstein**, David G. Hendrickson** *contributed equally **Corresponding Authors Abstract Replicative senescence (RS) as a model has become the central focus of research into cellular aging in vitro. Despite decades of study, this process through which cells cease dividing is not fully understood in culture, and even much less so in vivo during development and with aging. Here, we revisit Hayflick’s original observation of RS in WI-38 human fetal lung fibroblasts equipped with a battery of high dimensional modern techniques and analytical methods to deeply profile the process of RS across each aspect of the central dogma and beyond. We applied and integrated RNA-seq, proteomics, metabolomics, and ATAC-seq to a high resolution RS time course. We found that the transcriptional changes that underlie RS manifest early, gradually increase, and correspond to a concomitant global increase in accessibility in nucleolar and lamin associated domains. During RS WI-38 fibroblast gene expression patterns acquire a striking resemblance to those of myofibroblasts in a process similar to the epithelial to mesenchymal transition (EMT).
    [Show full text]